Evolent Health (NYSE:EVH) reported Q2 EPS of $0.10, $0.05 better than the analyst estimate of $0.05. Revenue for the quarter came in at $319.9 million versus the consensus estimate of $298.79 million.
GUIDANCE:
Evolent Health sees FY2022 revenue of $1.32-1.36 billion, versus the consensus of $1.22 billion.
Evolent Health sees Q3 2022 revenue of $343-363 million, versus the consensus of $312.7 million.